Literature DB >> 8806248

Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study.

H H Parving1, P Jacobsen, L Tarnow, P Rossing, L Lecerf, O Poirier, F Cambien.   

Abstract

OBJECTIVE: To evaluate the concept that an insertion/deletion polymorphism of the angiotensin converting enzyme gene predicts the therapeutic efficacy of inhibition of angiotensin converting enzyme on progression of diabetic nephropathy.
DESIGN: Observational follow up study of patients with insulin dependent diabetes and nephropathy who had been treated with captopril for a median of 7 years (range 3-9 years).
SETTING: Outpatient diabetic clinic in a tertiary referral centre. PATIENTS: 35 patients with insulin dependent diabetes and nephropathy were investigated during captopril treatment (median 75 mg/day (range 12.5 to 150 mg/day)) that was in many cases combined with a loop diuretic, 11 patients were homozygous for the deletion allele and 24 were heterozygous or homozygous for the insertion allele of the angiotensin converting enzyme gene. MAIN OUTCOME MEASURES: Albuminuria, arterial blood pressure, and glomerular filtration rate according to insertion/deletion polymorphism.
RESULTS: The two groups had comparable glomerular filtration rate, albuminuria, blood pressure, and haemoglobin A1c concentration at baseline. Captopril induced nearly the same reduction in mean blood pressure in the two groups-to 103 (SD 5) mm Hg in the group with the deletion and 102 (8) mm Hg in the group with the insertion-and in geometric mean albumin excretion-573 (antilog SE 1.3) micrograms/min and 470 (1.2) micrograms/min, respectively. The rate of decline in glomerular filtration rate (linear regression of all glomerular filtration rate measurements during antihypertensive treatment) was significantly steeper in the group homozygous for the double deletion allele than in the other group (mean 5.7 (3.7) ml/min/year and 2.6 (2.8) ml/min/year, respectively; P = 0.01). Multiple linear regression analysis showed that haemoglobin A1c concentration, albuminuria, and the double deletion genotype independently influenced the sustained rate of decline in glomerular filtration rate (R1 (adjusted) = 0.51).
CONCLUSION: The deletion polymorphism in the angiotensin converting enzyme gene reduces the long term beneficial effect of angiotensin converting enzyme inhibition on the progression of diabetic nephropathy in patients with insulin dependent diabetes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8806248      PMCID: PMC2352037          DOI: 10.1136/bmj.313.7057.591

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  19 in total

1.  Selection of routine method for determination of glomerular filtration rate in adult patients.

Authors:  J Bröchner-Mortensen; P Rödbro
Journal:  Scand J Clin Lab Invest       Date:  1976-01       Impact factor: 1.713

2.  Radioimmunoassay for urinary albumin using a single antibody.

Authors:  D W Miles; C E Mogensen; H J Gundersen
Journal:  Scand J Clin Lab Invest       Date:  1970-08       Impact factor: 1.713

3.  Controlled, randomised trial of the effect of dietary fat on blood pressure.

Authors:  P Puska; J M Iacono; A Nissinen; H J Korhonen; E Vartianinen; P Pietinen; R Dougherty; U Leino; M Mutanen; S Moisio; J Huttunen
Journal:  Lancet       Date:  1983-01-01       Impact factor: 79.321

Review 4.  Current status on assessment and measurement of glomerular filtration rate.

Authors:  J Brøchner-Mortensen
Journal:  Clin Physiol       Date:  1985-02

Review 5.  The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies.

Authors:  T H Hostetter; H G Rennke; B M Brenner
Journal:  Am J Med       Date:  1982-03       Impact factor: 4.965

6.  A prospective study of glomerular filtration rate and arterial blood pressure in insulin-dependent diabetics with diabetic nephropathy.

Authors:  H H Parving; U M Smidt; B Friisberg; V Bonnevie-Nielsen; A R Andersen
Journal:  Diabetologia       Date:  1981-04       Impact factor: 10.122

7.  Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy.

Authors:  H Yoshida; T Mitarai; T Kawamura; T Kitajima; Y Miyazaki; R Nagasawa; Y Kawaguchi; H Kubo; I Ichikawa; O Sakai
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

8.  Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy.

Authors:  H H Parving; E Hommel; U M Smidt
Journal:  BMJ       Date:  1988-10-29

9.  Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy.

Authors:  G G van Essen; P L Rensma; D de Zeeuw; W J Sluiter; H Scheffer; A J Apperloo; P E de Jong
Journal:  Lancet       Date:  1996-01-13       Impact factor: 79.321

10.  Polymorphisms in angiotensin-converting-enzyme gene and progression of IgA nephropathy.

Authors:  P N Harden; C Geddes; P A Rowe; J H McIlroy; M Boulton-Jones; R S Rodger; B J Junor; J D Briggs; J M Connell; A G Jardine
Journal:  Lancet       Date:  1995-06-17       Impact factor: 79.321

View more
  26 in total

Review 1.  Angiotensin I-converting enzyme: genotype and disease associations.

Authors:  D Crisan; J Carr
Journal:  J Mol Diagn       Date:  2000-08       Impact factor: 5.568

Review 2.  The impact of molecular medicine upon early cardiovascular drug development.

Authors:  M W Lunnon; M Braddock
Journal:  Br J Clin Pharmacol       Date:  2000-07       Impact factor: 4.335

Review 3.  Drug-gene interactions between genetic polymorphisms and antihypertensive therapy.

Authors:  Hedi Schelleman; Bruno H Ch Stricker; Anthonius De Boer; Abraham A Kroon; Monique W M Verschuren; Cornelia M Van Duijn; Bruce M Psaty; Olaf H Klungel
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 4.  Diabetic nephropathy. Its relationship to hypertension and means of pharmacological intervention.

Authors:  T Baba; S Neugebauer; T Watanabe
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

Review 5.  Genetic predisposition and renal allograft failure: implication of non-HLA genetic variants.

Authors:  Faisal Khan; Swati Agrawal; Suraksha Agrawal
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

6.  The angiotensin-I converting enzyme gene I/D variation contributes to end-stage renal disease risk in Chinese patients with type 2 diabetes receiving hemodialysis.

Authors:  Ming Lu; Jianzhong Zhang; Ming Li; Xiaoxu Ge; Xu Dai; Jiao Zhao; Mingzhou Fu; Tao Wang; Xiyao Fang; Can Li; Rong Zhang; Weijing Zhao; Taishan Zheng; Feng Wang; Ming Yu; Tao Lei; Niansong Wang; Yuqian Bao; Limei Liu; Yanjun Liu; Weiping Jia
Journal:  Mol Cell Biochem       Date:  2016-09-16       Impact factor: 3.396

7.  Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005.

Authors:  P Rossing
Journal:  Diabetologia       Date:  2005-12-09       Impact factor: 10.122

8.  Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy.

Authors:  M Marre; G Chatellier; F Alhenc-Gelas
Journal:  BMJ       Date:  1996-12-14

Review 9.  Lisinopril. A review of its pharmacology and use in the management of the complications of diabetes mellitus.

Authors:  K L Goa; M Haria; M I Wilde
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

Review 10.  Risk predictors in patients with diabetic nephropathy.

Authors:  P Fioretto; M L Caramori; M Dalla Vestra; M Mauer
Journal:  Curr Diab Rep       Date:  2001-12       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.